Page 9 - Pharma Sector

Torrent Pharma share pops 4% on ₹25,689-cr JB Chem deal; analysts cautious

Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore.

Why is Alembic Pharmaceuticals' share in demand today? Key details here

Alembic Pharmaceuticals share surged after the company received final approval from the USFDA for its ANDA for Doxorubicin Hydrochloride Liposome Injection in two dosage strength.

Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation

Torrent Pharma will acquire KKR's 46.39% stake in JB Pharma followed by open offer and merger, strengthening chronic segment and CDMO footprint in India and abroad

Torrent Pharma in advanced talks to acquire JB Chemicals from KKR

Torrent Pharma is negotiating to acquire JB Chemicals from KKR in a deal that may trigger an open offer, strengthening its position in the domestic pharma market

Biocon Biologics to launch Eylea biosimilar Yesafili in Canada next month

Yesafili is the first Eylea biosimilar approved in Canada and Biocon Biologics' 10th commercialised biosimilar, with launch scheduled for July 4 across the country

JP Morgan upgrades Torrent Pharma to 'Overweight', lifts target; stk up 5%

Torrent Pharma share price rose after JPMorgan reportedly upgraded the company to 'Overweight'. The brokerage also hiked the target price to ₹3,800, from ₹3,650 earlier.

India approves Eli Lilly's Mounjaro pen for diabetes, weight control

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 diabetes and chronic weight management

AstraZeneca sets up ₹166 cr Global Hub to boost AI driven healthcare

Global bio-pharmaceutical company AstraZeneca has established its state-of-the-art Global Hub in Bengaluru investing Rs 166 crore to focus on development of AI-powered healthcare solutions, a top official said on Thursday. This marks the second major investment by AstraZeneca in July 2024 after it announced expansion of its Global Innovation and Technology Centre in Chennai with an outlay of Rs 250 crore. The new facility in Bengaluru is designed to accommodate nearly 1,300 employees including 400 new jobs. It will support the company's capabilities in AI-powered innovation across Research and Development, global business services, Information Technology and digital health operations, among others. The Global Hub in Bengaluru is dedicated to Research and Development, Global Business Services, Information Technology while the Global Innovation and Technology Centre in Chennai serves as a strategic hub for IT, Global Business Services. Following the expansion of the facility, the ...

Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra

Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India, following approval by the Central Drugs Standard Control Organisation.

Novo Nordisk launches Wegovy in India to tackle obesity and heart risk

Wegovy is India's first weekly injectable approved for both long-term weight loss and reducing heart risks in obese and overweight adults

Kashmik Formulation targets ₹100 crore revenue in FY26, eyes IPO

The company currently produces around 25 crore units a month and is expanding its ground and first-floor production facilities to meet rising demand

USFDA approves first HIV prevention shot needing only two doses a year

Lenacapavir, the world's first twice-yearly HIV prevention shot, gets US FDA nod-offering a discreet, long-acting solution and near-complete protection to boost global HIV prevention efforts

Lupin, Sino Universal sign agreement to launch Tiotropium DPI in China

Tiotropium DPI, known for improving lung function and quality of life in patients with respiratory diseases, supports the aim to expand access to quality healthcare solutions in China

Largecap segment shines in Q4 amid broad sectoral divergence: Equirus Sec

Of the 270 companies analysed, largecaps saw a 6 per cent Y-o-Y earnings rise, midcaps gained 2 per cent, while smallcaps slumped 16 per cent.

Upcoming pharma park to position UP as bulk drug manufacturing hub

The Uttar Pradesh government is betting big on the upcoming pharma park in Lalitpur, which is expected to position the state alongside Gujarat and Andhra Pradesh as one of India's leading bulk drug manufacturing hubs. The project in the Bundelkhand region is expected to attract investments exceeding Rs 12,000 crore, according to the Uttar Pradesh State Industrial Development Authority (UPSIDA). Speaking to PTI, Mayur Maheshwari, Chief Executive Officer of UPSIDA, said, "The pharma park project in Lalitpur is one of the state government's landmark initiatives. It is entirely state-sponsored, aimed at achieving self-reliance in bulk drug and API manufacturing. The idea is for Uttar Pradesh to take the lead." Spread over 1,472 acres, the project has entered its first phase with 353 acres already under development. "We have secured environmental clearances and allotments for the first phase have begun," Maheshwari added. The project also lays thrust on having Zero Liquid Discharge (ZLD

Sun Pharma starts succession plan; Ganorkar succeeds Shanghvi as MD

Dilip Shanghvi to remain executive chairman while Ganorkar takes charge as MD from September 1 and Aalok Shanghvi is given additional charge of North America business

Sun Pharma appoints Kirti Ganorkar as MD after shareholders' approval

Gonarkar has been heading Sun Pharma's India business since 2019 and has previously held roles in marketing, new product introduction, among others, within the company

Why is Jubilant Pharmova share price buzzing in an overall weak market?

Jubilant Pharmova shares rose after its board approved the slump sale of its API business to wholly-owned subsidiary, Jubilant Biosys.

Bharat Biotech, GSK partner to develop vaccine for Shigella diarrhoea

Bharat Biotech on Thursday said it has partnered with GSK plc for the development of a vaccine for Shigellosis, a severe form of bacterial diarrhoea. The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates globally, the company said in a statement. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative Generalized Modules for Membrane Antigens (GMMA)-based platform, and robust early clinical results, it added. "With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries," Bharat Biotech Executive Chairman Krishna Ella said. As part of this agreement, Bharat Biotech will lead the further development of ...

Pharma body seeks rethink on entry curbs of MRs in govt hospitals

Indian Pharmaceutical Alliance warns that the DGHS ban on medical representatives may affect public health, slow innovation and result in pharma sector job losses